Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors
Jonathan G Pol1,2,3,4,5, Sarah Lévesque1,2,3,4,5, Samuel T Workenhe6,7,8
1Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
Abstract:
Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.
Related Concept Videos
Tumor Immunotherapy
Metallic Solids
All metallic solids exhibit high thermal and electrical conductivity, metallic luster, and malleability....
Structures of Solids
Clinical Trials: Overview
Trial and Error and Algorithm
Network Covalent Solids
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...


